Kymriah Archives -

News/ News/ News/ Oncology/ Sales and Marketing

Gilead claims first CAR-T approval for leukaemia in older adults

Phil Taylor acute lymphoblastic leukaemia, Gilead Sciences, immuno-oncology, Kite Pharma, Kymriah, Novartis, Oncology, regulatory approval, Tecartus 0 Comment

Gilead Sciences’ Kite Pharma unit has carved out a niche for its CD19-targeted CAR-T therapy Tecartus in acute

Gilead claims first CAR-T approval for leukaemia in older adults

https://pharmaphorum.com/news/gilead-claims-first-car-t-approval-for-leukaemia-in-older-adults/

Market Access/ News/ News/ News/ Oncology

Kymriah is first CAR-T cleared for follicular lymphoma in EU

Phil Taylor CAR-T therapies, cell therapy, Gilead Sciences, immuno-oncology, Kymriah, Novartis, Oncology, regulatory approval, Yescarta 0 Comment

Novartis’ CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of

Kymriah is first CAR-T cleared for follicular lymphoma in EU

https://pharmaphorum.com/news/kymriah-is-first-car-t-cleared-for-follicular-lymphoma-in-eu/

News/ News/ Oncology

Kite claims a first for CAR-T Tecartus in adult leukaemia

Phil Taylor acute lymphoblastic leukaemia, Gilead Sciences, immuno-oncology, Kite Pharma, Kymriah, Novartis, Oncology, regulatory approval, Tecartus 0 Comment

The FDA has approved Kite Pharma’s Tecartus as a treatment for adults with relapsed or refractory B-cell precursor

Kite claims a first for CAR-T Tecartus in adult leukaemia

https://pharmaphorum.com/news/kite-claims-a-first-for-car-t-tecartus-in-adult-leukaemia/

News/ News/ Oncology

Novartis’ bid to extend Kymriah into earlier use hits a roadblock

Phil Taylor CAR-T therapies, diffuse B-Cell lymphoma, immuno-oncology, Kymriah, non-Hodgkin lymphoma, Novartis, Oncology 0 Comment

Novartis’ CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few

Novartis’ bid to extend Kymriah into earlier use hits a roadblock

https://pharmaphorum.com/news/novartis-bid-to-extend-kymriah-into-earlier-use-hits-a-roadblock/

News/ News/ Oncology

ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus data

Phil Taylor acute lymphoblastic leukaemia, ASCO 2021, CAR-T therapies, Gilead Sciences, Kite Pharma, Kymriah, Novartis, Oncology, Tecartus 0 Comment

Novartis’ Kymriah has had the CAR-T therapy market for acute lymphoblastic leukaemia (ALL) to itself so far, but

ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus data

https://pharmaphorum.com/news/asco21-gilead-sets-up-first-fda-okay-for-adult-all-with-tecartus-data/

R&D/ Views & Analysis/ Views and analysis

Casting aside CRISPR scissors and making a point with base editors

mike.hammerton@pharmaphorum.com CRISPR, gene editing, immune cell therapy, Kymriah, Perkin Elmer, Yescarta 0 Comment

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at

Casting aside CRISPR scissors and making a point with base editors

https://pharmaphorum.com/r-d/views-analysis-r-d/immune-cell-therapies-crispr-cas9-gene-editing/

News/ News/ Oncology/ Top stories

FDA hastens development of Novartis’ Kymriah in follicular lymphoma

Richard Staines blood cancer, cancer, CAR T, fda, follicular lymphoma, Kymriah, Novartis, R&D, regulation 0 Comment

Novartis will receive extra help from the FDA during the development of its CAR-T cancer cell therapy Kymriah

FDA hastens development of Novartis’ Kymriah in follicular lymphoma

https://pharmaphorum.com/news/fda-hastens-development-of-novartis-kymriah-in-follicular-lymphoma/

News/ News/ News/ Oncology/ Patients

Real-world data backs Kymriah’s safety profile, says Novartis

Phil Taylor acute lymphoblastic leukaemia, Haematology, Kymriah, Non-Hodgkins Lymphoma, Novartis, real world data 0 Comment

With more competition looming for its CAR-T therapy Kymriah, Novartis has pointed to new data that show the

Real-world data backs Kymriah’s safety profile, says Novartis

https://pharmaphorum.com/news/real-world-data-backs-kymriahs-safety-profile-says-novartis/

Market Access/ News/ News

Novartis’ Kymriah okayed for funding in Scotland for lymphoma

Richard Staines Kymriah, lymphoma, SMC 0 Comment

Novartis’ Kymriah has become the first CAR-T available to NHS patients across the UK after Scotland’s medicines cost-effectiveness

Novartis’ Kymriah okayed for funding in Scotland for lymphoma

https://pharmaphorum.com/news/novartis-kymriah-okayed-for-funding-in-scotland-for-lymphoma/

Trending

Kymriah

Login